| Literature DB >> 31851363 |
Thorsten Feldkamp1,2, Anja Bienholz1, Andreas Paul3, Fuat H Saner3.
Abstract
BACKGROUND: Patients following liver transplantation are at risk to develop acute kidney injury (AKI). The aim of our study was to assess risk factors for the development of AKI and the impact of AKI on the outcome of patients after liver transplantation (OLT). PATIENTS AND METHODS: In this retrospective study, we analyzed 149 patients undergoing OLT from 1/2004 to 12/2007. AKI was defined according to the KDIGO definition representing the AKIN and the RIFLE classification, and according to the need for renal replacement therapy (RRT).Entities:
Keywords: Transplantation; acute kidney injury; cirrhosis; renal replacement
Year: 2020 PMID: 31851363 PMCID: PMC6944654 DOI: 10.1042/BSR20191187
Source DB: PubMed Journal: Biosci Rep ISSN: 0144-8463 Impact factor: 3.840
Figure 1Study design
ICU: Intensive care unit, AKI: acute kidney injury, AKIN: Acute Kidney Injury Network, RIFLE: Risk Injury Failure Loss of function End stage renal disease, RRT: renal replacement therapy
Diagnosis leading to transplantation
| Diagnosis | Number of patients |
|---|---|
| Alcoholic related cirrhosis | 31 |
| HBV | 25 |
| HCV | 35 |
| ALF | 13 |
| Cryptogenic | 15 |
| PSC | 13 |
| Autoimmune | 6 |
| NET | 5 |
| Miscellaneous | 19 |
| Total | 162 |
Miscellaneous includes: alpha-1 antitrypsine deficiency (2), Budd-Chiari syndrome (4), Liver angio sarcoma (1), Liver cystadeno carcinoma (1), hemochromatosis (1), primary hepatocellular carcinoma without cirrhosis (1), primary biliary cirrhosis (2) secondary biliary cirrhosis (2), secondary sclerozing cholangitis (1), Wilson’s disease (3).
Abbreviations: ALF, acute liver failure; HBV, hepatitis B virus; HCV, hepatitis C virus; NET, neuroendocrine tumor; PSC, primary sclerozing cholangitis.
Comparison of pre and intraoperative factors and postoperative complications according to the AKI group
| No AKI | AKI no RRT (AKIN+RIFLE) | AKI no RRT (AKIN only) | AKI + RRT (AKIN+RIFLE) | ||
|---|---|---|---|---|---|
| Male | 29 (56.7%) | 22 (73.3%) | 9 (64.3%) | 34 (63.0%) | |
| Age (years) | 51 ± 11 | 50 ± 12 | 48 ± 14 | 46 ± 13 | |
| Weight (kg) | 75 ± 12 | 80 ± 16 | 78 ± 13 | 79 ± 18 | |
| Height (cm) | 172 ± 8 | 173 ± 8 | 175 ± 12 | 173 ±10 | |
| BMI (kg/m2) | 25 ± 3 | 27 ± 4 | 26 ± 4 | 26 ± 5 | |
| MELD | 13.4 ± 6.6 | 15.2 ± 6.2 | 17.8 ± 6.9* | 23.2 ± 10.1‡ | *0.05 vs. No AKI ‡ <0.01 vs. No AKI |
| SCr pre (mg/dl) | 1.08 ± 0.37 | 1.10 ± 0.31 | 1.21 ± 0.63 | 1.65 ± 1.01‡ | ‡ <0.01 vs. No AKI |
| Bilirubin pre (mg/dl) | 4.3 ± 7.0 | 5.1 ± 5.7 | 7.2 ± 8.7 | 10.0 ± 10.0‡ | ‡ <0.01 vs. No AKI |
| INR | 1.35 ± 0.51 | 1.37 ± 0.39 | 1.49 ± 0.51 | 1.59 ± 0.52‡ | ‡ <0.03 vs. No AKI |
| ICU stay (days) | 5.4 ± 2.7 | 8.0 ± 5.01† | 10.8 ± 12.4* | 21.7 ± 21.4‡ | † 0.01 vs. No AKI * 0.04 vs. No AKI ‡ <0.01 vs. No AKI |
| Ventilation time (hours) | 87 ± 227 | 115 ± 232 | 154 ± 220 | 736 ± 846‡ | ‡ <0.01 vs. No AKI |
| CIT (min) | 409 ± 185 | 418 ± 212 | 452 ± 201 | 411 ± 172 | |
| WIT (min) | 33 ± 8 | 37 ± 11 | 39 ± 19 | 74 ± 214 | |
| Tranfusion (units of RPC) | 0.8 ± 1.7 | 2.1 ± 3.9 | 1.5 ± 2.5 | 5.9 ± 6.6‡ | ‡ <0.01 vs. No AKI |
AKI: acute kidney injury
AKIN: Acute Kidney Injury Network
RIFLE: Risk Injury Failure Loss of function End stage renal disease
RRT: renal replacement therapy
BMI: body mass index
CIT: cold ischemia time; WIT: warm ischemia time
RPC: Red packed cells
Pre: preoperative
Values are shown as the mean ± standard deviation.
Univariate analysis of pre and intraoperative factors and postoperative complications for the development of AKI
| AKI (AKIN+RIFLE) | AKI (AKIN only) | AKI (RRT) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Gender | 0.14 | 2.09 | 0.78–5.56 | 0.62 | 1.37 | 0.40–4.65 | 0.52 | 1.29 | 0.59–2.82 |
| Age | 0.81 | 1.00 | 0.96–1.04 | 0.39 | 0.98 | 0.93–1.03 | 0.08 | 0.97 | 0.94–1.00 |
| Weight (kg) | 0.10 | 1.03 | 0.99–1.06 | 0.40 | 1.02 | 0.97–1.07 | 0.22 | 1.02 | 0.99–1.04 |
| Height (cm) | 0.64 | 1.01 | 0.96–1.07 | 0.37 | 1.03 | 0.96–1.10 | 0.60 | 1.01 | 0.97–1.05 |
| BMI (kg/m2) | 0.12 | 1.10 | 0.98–1.25 | 0.71 | 1.03 | 0.87–1.23 | 0.29 | 1.05 | 0.96–1.16 |
| MELD | 0.26 | 1.04 | 0.97–1.12 | 0.05 | 1.09 | 1.00–1.19 | <0.01 | 1.15 | 1.08–1.22 |
| SCr pre (mg/dl) | 0.78 | 1.21 | 0.33–4.38 | 0.34 | 1.82 | 0.54–6.16 | <0.01 | 5.23 | 1.96–14.02 |
| Bilirubin pre (mg/dl) | 0.63 | 1.02 | 0.95–1.09 | 0.21 | 1.05 | 0.98–1.12 | <0.01 | 1.09 | 1.03–1.16 |
| INR | 0.85 | 1.10 | 0.42–2.86 | 0.39 | 1.57 | 0.56–4.41 | 0.03 | 3.15 | 1.13–8.73 |
| CIT (min) | 0.84 | 1.00 | 1.00–1.00 | 0.46 | 1.00 | 1.00–1.00 | 0.94 | 1.00 | 1.00–1.00 |
| WIT (min) | 0.17 | 1.03 | 0.99–1.08 | 0.16 | 1.04 | 0.99–1.09 | 0.06 | 1.04 | 1.00–1.08 |
| ICU stay (days) | 0.01 | 1.22 | 1.05–1.42 | 0.04 | 1.16 | 1.00–1.35 | <0.01 | 1.32 | 1.16–1.50 |
| Ventilation time (h) | 0.59 | 1.00 | 1.00–1.00 | 0.35 | 1.00 | 1.00–1.00 | <0.01 | 1.01 | 1.00–1.01 |
| Tranfusion (units of RPC) | 0.08 | 1.22 | 0.98–1.51 | 0.23 | 1.19 | 0.90–1.57 | <0.01 | 1.76 | 1.36–2.27 |
AKI: acute kidney injury
AKIN: Acute Kidney Injury Network
RIFLE: Risk Injury Failure Loss of function End stage renal disease
RRT: renal replacement therapy
BMI: body mass index
CIT: cold ischemia time; WIT: warm ischemia time
Pre: preoperative
Multivariate analysis of preoperative factors and postoperative complications for the development of AKI
| AKI (AKIN+RIFLE) | AKI (AKIN only) | AKI (RRT) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| SCr pre (mg/dl) | n.s. | n.s. | 0.01 | 3.71 | 1.32–10.42 | ||||
| Bilirubin pre (mg/dl) | n.s. | n.s. | 0.18 | 0.93 | 0.81–1.07 | ||||
| INR | n.s. | n.s. | 0.73 | 0.11 | 0.01–1.14 | ||||
| ICU stay (days) | 0.05 | 1.16 | 1.00–1.35 | 0.01 | 1.22 | 1.05–1.42 | 0.20 | 1.09 | 0.96–1.23 |
| Ventilation time (h) | n.s. | n.s. | <0.01 | 1.00 | 1.00–1.01 | ||||
| Tranfusion (units of RPC) | n.s. | n.s. | 0.03 | 1.49 | 1.05–2.11 | ||||
AKI: acute kidney injury
AKIN: Acute Kidney Injury Network
RIFLE: Risk Injury Failure Loss of function End stage renal disease
RRT: renal replacement therapy
BMI: body mass index
CIT: cold ischemia time; WIT: warm ischemia time
Pre: preoperative
Patient survival
| Survival | Median (days) | 95% CI | 28 d (%) | 1 year (%) | 3 year (%) | |
|---|---|---|---|---|---|---|
| No AKI | 1561 | 1380–1742 | 100 | 92.2 | 90.2 | |
| AKI (AKIN+RIFLE) | 1179 | 1281–1706 | 93.3 | 93.3 | 93.3 | 1.000 |
| AKI (AKIN only) | 1494 | 744–1613 | 100 | 71.4 | 71.4 | 0.068 |
| AKI (RRT) | 86 | 0*–310 | 70.4 | 46.4 | 44.4 | <0.001 |
Log rank test for analysis of the effect of the degree of renal injury on patient survival
AKI: acute kidney injury
AKIN: Acute Kidney Injury Network
RIFLE: Risk Injury Failure Loss of function End stage renal disease
RRT: renal replacement therapy
CI: confidence interval
*Lower border of the confidence interval was set to 0 for logical reasons.
Figure 2Kaplan–Meier survival curves for the different degree of renal injury
Survival was dramatically reduced in patients experiencing acute kidney injury requiring renal replacement therapy (RRT, N = 54) compared with patient without acute kidney injury (No AKI, N = 51), patients with acute kidney injury according to the AKIN criteria (AKI only, N = 14) and patients with acute kidney injury according to the AKIN and RIFLE criteria (AKIN and RIFLE, N = 30). There was no patient, who developed acute kidney injury according to the RIFLE criteria only (AKIN: acute kidney injury network, AKI: acute kidney injury, RRT: renal replacement treatment).
Cox regression multivariate analysis of the effect of different factors on patient survival
| 28 d (%) | 1 year (%) | 3 year (%) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | HR | 95% CI | ||||
| Transfusion | < 0.001 | 1.08 | 1.04-1.12 | 0.049 | 1.05 | 1.00–1.11 | 0.115 | ||
| AKI (RRT) | <0.001 | 10.63 | 3.48–32.45 | <0.001 | 8.46 | 3.06–23.40 | |||
| Ventilation time | – | 0.646 | 0.295 | ||||||
| ICU stay | – | 0.260 | – | ||||||
HR: Hazard ratio
AKI: acute kidney injury
AKIN: Acute Kidney Injury Network
RIFLE: Risk Injury Failure Loss of function End stage renal disease
RRT: renal replacement therapy
CI: confidence interval
Due to the fact that there were no death in the No AKI group a hazard ratio could not be calculated. The logrank test for 28 days survival of AKI (RRT) vs. no AKI was highly significant (logrank P < 0.001).